9 stories found
Moderna and Merck announced positive late-stage trial results for their mRNA-based cancer vaccine, which significantly reduced the recurrence of melanoma. This breakthrough led to a substantial surge in Moderna's stock price and a broader rally in the biopharma sector.
Pilgrim's Pride has outlined a 2.5% U.S. supply growth for the second half of 2026, maintaining its capital expenditure at $900 million. Marcus also detailed its 2026 capital expenditure plans, with group pace running 3% ahead for the year.
Pilgrim's Pride has outlined capital expenditure plans of $900 million to $950 million for 2026, as its Q1 adjusted EBITDA margin dropped to 6.8%.
JBS has made a proposal to acquire the remaining shares of Pilgrim's Pride, a move that analysts are calling attractive. This bid would give JBS full control over the poultry producer.
Several companies, including Plexus, Preformed Line Products, Endeavour Silver, Cactus, Spok, Insperity, Arxis, CONMED, and Everest Group, reported their latest quarterly earnings, with most beating analyst expectations for EPS and revenue. Starbucks, however, saw a significant decline in international revenue, and Pilgrim's Pride missed on both EPS and revenue.
Several companies, including Pilgrim's Pride, First Interstate Banc, and Alkami Technology, have released their latest financial results, with some reporting GAAP EPS and revenue figures, while others provided Q1 2026 earnings previews.
JBS-backed Pilgrim's Pride is set to acquire Walkers, a UK pork firm, from Samworth Brothers.
An analyst report provides insights and commentary on Pilgrim's Pride Corporation.
Strong profits in the US chicken market have led BMO Capital to raise its target price for Pilgrim's Pride (PPC).